GlassScriptPhysician profile
Justin V Bartos
NPI 1720087349
$1,408.26
in general payments reported to CMS, 2019-2025
23 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $29.13 · 2023: $136 · 2024: $303 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $191.63 | 2019-2024 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $136.32 | 2023 | Leqvio |
| Abbvie INC. | $113.17 | 2019 | |
| Amarin Pharma, INC. | $103.99 | 2024 | |
| Gilead Sciences, INC. | $101.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.94 | 2019 | |
| Novo Nordisk INC | $79.38 | 2024 | |
| Pfizer INC. | $66.09 | 2019-2020 | |
| Astellas Pharma US INC | $53.69 | 2019 | |
| Endo Pharmaceuticals INC. | $43.16 | 2019 | |
| Lilly USA, LLC | $30.32 | 2019 | |
| Abbott Laboratories | $26.47 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $23.73 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $22.99 | 2025 | Nuzyra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $22.99 | 2025 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $19.74 | 2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $17.50 | 2025 | Gardasil 9, Capvaxive |
| Boston Scientific Corporation | $15.35 | 2019 | |
| Amgen INC. | $15.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.35 | 2019 | |
| Duchesnay USA Incorporated | $12.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Bartos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.